The effect of succinate-containing dialysis solution on the symptoms of CKD C5d stage

BACKGROUND. Attempts to improve the clinical outcomes of hemodialysis (HD) treatment through interventions aimed at improving quantitative indicators of uremia correction are not effective enough. The guidelines of professionals for different treatment outcomes differ from the interests and preferences of patients. THE AIM: to evaluate the possibilities of improving symptoms in HD patients by changing the composition of dialysis solution from standard to succinate-containing (SCDS). PATIENTS AND METHODS. The cohort study included 137 patients from one dialysis center. Symptoms were assessed by the Dialysis Symptom Index (DSI). RESULTS. Initially, the median score on the questionnaire was 21 [13.25–37.75], after a year – 25.0 [14.0–38.7]; the median of individual dynamics did not differ from 0 (0,0 [-4,7–9,0], p=0.407). At the same time, the dynamics of DSI in the group of those transferred to SCDS differed from that in the stable mode group: -1 (-12-5.75) vs. 3.5 (-2.25–16.5): Z=-2.714; p=0.007. In a one-factor logistic analysis, switching to SCDS reduced the risk of worsening the symptoms of whole DSI by 75.9 %: OR 0.241 (0.099-0.587); p=0.002, as well as for the mental and bodily components (OR 0.296 (0.123-0.709, p=0.006) and 0.389 (0.163-0.927, p=0.033), respectively). In the multifactorial logistic analysis model, significant factors were: the fact of conversion to SCDS, higher levels of albumin (-5 % risk per 0.1 mmol/l), hemoglobin (-41 % risk per 10 g/l), as well as a higher ultrafiltration rate (+17 % per 1 ml/hour/kg) and a higher phosphate level (+ 8 % per 0.1 mmol/l). CONCLUSION. The use of a succinate-containing dialysis solution in comparison with the standard one can improve the dynamics of DSI. Additional significant factors related to the dynamics of symptoms are the initial levels of albumin, hemoglobin, phosphates in the blood, and the rate of ultrafiltration.

1. Zhu Y, Li J, Lu H et al. Effect of hemodiafiltration and hemodialysis on mortality of patients with end-stage kidney disease: a meta-analysis. BMC Nephrol 2024;25(1):372. doi: 10.1186/s12882-024-03810-9.

2. Chung EY, Palmer SC, Saglimbene VM et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2023;2(2):CD010590. doi: 10.1002/14651858.CD010590.pub3

3. Ku E, Del Vecchio L, Eckardt KU et al; for Conference Participants. Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2023;104(4):655–680. doi: 10.1016/j.kint.2023.05.009

4. Ketteler M, Evenepoel P, Holden RM et al; Conference Participants. Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2025;107(3):405–423. doi: 10.1016/j.kint.2024.11.013

5. Flythe JE, Chang TI, Gallagher MP et al; Conference Participants. Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2020;97(5):861–876. doi: 10.1016/j.kint.2020.01.046

6. Johal N, Sharma R, Belcher J et al. Centre-level fluid management practices in the BISTRO trial and their lack of association with participant fluid status and blood pressure in non-anuric haemodialysis patients. BMC Nephrol 2024;25(1):398. doi: 10.1186/s12882-024-03837-y

7. Abdulaziz HMM, Sabry A, Saleh M, El-Said G. Oral Sodium Bicarbonate vs. Use of Higher Dialysate Bicarbonate in Hemodialysis Patients With Metabolic Acidosis: A Randomized Controlled Trial. Hemodial Int 2025 Mar 14. doi: 10.1111/hdi.13230. Epub ahead of print

8. Molnar AO, Killin L, Bota S et al. Association Between the Dialysate Bicarbonate and the Pre-dialysis Serum Bicarbonate Concentration in Maintenance Hemodialysis: A Retrospective Cohort Study. Can J Kidney Health Dis 2024;11:20543581241256774. doi: 10.1177/20543581241256774

9. Mehrotra R, Davison SN, Farrington K et al; Conference Participants. Managing the symptom burden associated with maintenance dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2023;104(3):441–454. doi: 10.1016/j.kint.2023.05.019

10. Al-Barbari K, Vishnevskii KA, Karpov PA et al. Hemodialysis treatment outcomes and patient-reported outcomes in a single-center pilot study. Nephrology (Saint-Petersburg) 2025;29(1):75– 87. (In Russ.) doi: 10.36485/1561-6274-2025-29-1-75-87. EDN: BPMUEL

11. Vishnevskii KA, Parshina EV, Zemchenkov AYu et al. Analysis of patient's survival on renal replacement therapy in a large city: a multicenter prospective cohort observational study. Nephrology and Dialysis 2025;27(1):59–79. (In Russ.) doi: 10.28996/2618-9801-2025-1-59-79

12. Smirnov AV, Golubev RV, Vasiliev AN et al. Hemodynamic effects of succinate-containing dialyzing solution. Ter Arkh 2015;87(6):56–61. (in Russ). doi: 10.17116/terarkh201587656-61

13. Smirnov AV, Vasil'eva IA, Nesterova OB et al. Quality of life and cognitive functions in patients with end-stage renal failure on hemodialysis using a succinate-containing dialyzing solution. Terapevticheskii arkhiv 2014;86(6):11–17 (in Russ). doi: ter-arkhiv.ru/0040-3660/article/view/31470

14. Golubev RV, Smirnov AV. Expanding the frontiers of succinate-containing dialysate’s effects. Nephrology (Saint-Petersburg) 2017;21(1):19–24. (In Russ.). doi:10.24884/1561-6274-2017-21-1-19-24

15. Weisbord SD, Fried LF, Arnold RM et al. Development of a symptom assessment instrument for chronic hemodialysis patients: the Dialysis Symptom Index. J Pain Symptom Manage 2004;27(3):226–240. doi: 10.1016/j.jpainsymman.2003.07.004

16. Jakovenko AA, Rumyantsev ASh. The prevalence of protein-energy wasting in haemodialysis patients. Nephrology and Dialysis 2019;21(1):66–71. (In Russ.). doi:10.28996/2618-9801-2019-1-66-71

17. Lavrishcheva IV, Jakovenko AA, Rumyantsev ASh, Kulaeva NN. Epidemiology of presarcopenia/sarcopenia of haemodialysis patients. Nephrology and Dialysis 2019;21(3):320–325. (In Russ.). doi:10.28996/2618-9801-2019-3-320-325

18. Charytan DM, Winkelmayer WC, Granger CB et al; ADAPT Investigators. Effects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0 mmol/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia. Kidney Int 2025;107(1):169–179. doi: 10.1016/j.kint.2024.10.010

19. Marshall MR, Wang MY, Vandal AC, Dunlop JL. Low dialysate sodium levels for chronic haemodialysis. Cochrane Database Syst Rev 2024 Nov 5;11(11):CD011204. doi: 10.1002/14651858.CD011204.pub3

20. Bargnoux AS, Morena M, Rodriguez A et al. Monitoring of ionized magnesium in hemodialysis patients: A useful tool to allow a personalized prescription of dialysate composition. Clin Chim Acta 2024;552:117687. doi: 10.1016/j.cca.2023.117687

21. MyTEMP writing committee. Personalised cooler dialysate for patients receiving maintenance haemodialysis (My-TEMP): a pragmatic, cluster-randomised trial. Lancet 2022;400 (10364):1693–1703. doi: 10.1016/S0140-6736(22)01805-0

22. Ku E, Del Vecchio L, Eckardt KU et al; for Conference Participants. Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2023;104(4):655–680. doi: 10.1016/j.kint.2023.05.009

23. Wang S, DellaFera L, Dhanani L et al. Institutional Usage of Ferric Pyrophosphate Citrate (FPC) Delivered Via Dialysate in Reducing Erythropoiesis Stimulating Agents (ESAs) and IV Iron Cost. Hosp Pharm 2022;57(3):355–358. doi: 10.1177/00185787211032363

24. Nishiuchi Y, Shima H, Fukata Y et al. Hypersensitivity reactions to bicarbonate dialysate containing acetate: a case report with literature review. CEN Case Rep 2020;9(3):243–246. doi: 10.1007/s13730-020-00466-w

25. Rodríguez-Espinosa D, Cuadrado-Payán E, Rico N et al. Citrate Dialysate with and without Magnesium Supplementation in Hemodiafiltration: A Comparative Study Versus Acetate. Int J Mol Sci 2024;25(15):8491. doi: 10.3390/ijms25158491

26. Ureña-Torres P, Bieber B, Guebre-Egziabher F et al. Citric Acid-Containing Dialysate and Survival Rate in the Dialysis Outcomes and Practice Patterns Study. Kidney360 2021;2(4):666–673. doi: 10.34067/KID.0006182020